drugset / Trial / NCT02051673

Induction of Donor-Specific Tolerance in Recipients of Live Donor Stem Cell Infusion (Compassionate Use)

NCT02051673 ↗

Expanded access No longer available Talaris Therapeutics Inc. Northwestern University · collab

Summary

Four subjects were treated under compassionate use provisions under this study with facilitating cell therapy (FCRx)

Timeline

Start
—
Primary completion
—
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Background FCRx Cell therapy — —

Indications